How long do I have to appeal a Blue Cross Blue Shield AAT Augmentation denial?

Internal appeal window: Use the deadline in the current denial notice. External review window: Use the deadline in the final denial or external-review notice. Confirm the triggering event, filing route, and date against the complete current notice and governing document.

Blue Cross Blue Shield · AAT Augmentation · US health-plan appeal rights

AAT Augmentation denied for failing step therapy by Blue Cross Blue Shield?

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Appeal rights, levels, and deadlines depend on the plan type, jurisdiction, and current denial notice. Use the notice and governing plan document as the operational source, verify the filing route with the plan, and retain proof of submission.

Internal appeal window

Use the deadline in the current denial notice

External review window

Use the deadline in the final denial or external-review notice

What the reviewed Blue Cross Blue Shield policy says

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Specialty Pharmacy — AAT Augmentation (Prolastin-C / Glassia / Aralast NP / Zemaira)

The Blue Cross Blue Shield angle on AAT Augmentation

## Why BCBS Applies Step Therapy to AAT Augmentation

Step therapy (also called "fail-first") requires that a patient try one or more lower-cost treatments before the plan will approve the prescribed therapy. For AAT augmentation, a step-therapy denial is often a coverage-policy error or a misapplication of criteria, because AAT augmentation is the only pharmacological therapy specifically indicated for the underlying genetic deficiency — there is no therapeutically equivalent "step" drug. However, BCBS policies may require documentation that general COPD therapies (bronchodilators, inhaled corticosteroids) were tried and were insufficient before augmentation is approved.

## Why This Is Appealable

Many states have enacted step-therapy override laws requiring insurers to waive step requirements when (a) the required step drug is contraindicated or clinically inappropriate for the patient, (b) the patient has already tried and failed the required step, or (c) the step drug is not therapeutically equivalent to the prescribed drug. For a condition with a specific genetic cause and a specifically indicated therapy, argument (c) is often the strongest. ACA §2719 and ERISA §503 provide the federal appeal framework; state law may add additional protections. External review is available within 4 months of a final internal denial.

## Documentation to Gather

Prior treatment history: A chronological list of all bronchodilators, inhaled therapies, and other respiratory medications tried, with start/stop dates and documented clinical outcomes (exacerbation rates, PFT trends, hospitalizations).
Physician letter on therapeutic distinctness: A letter from the treating pulmonologist or AAT specialist explaining why AAT augmentation addresses the specific pathophysiological mechanism of the condition in a way that no required step drug does.
Diagnosis confirmation: Laboratory phenotype/genotype documentation confirming hereditary AAT deficiency (not simply COPD), establishing that this is a distinct condition from generic obstructive lung disease.
State step-therapy override law reference: If your state has a step-therapy override statute, your physician's letter should cite the applicable override ground (contraindication, prior failure, or therapeutic non-equivalence).

## Criteria-Mapping Structure

Obtain BCBS's step-therapy policy for this drug from its clinical policy bulletin. List each required step in the left column. In the right column, document either (a) the date you tried that step and the documented outcome, or (b) the clinical reason why that step is not therapeutically equivalent or is inappropriate. Reference the FDA prescribing label's approved indication to demonstrate the distinction between AAT augmentation and general COPD therapies.

## Timeline

1. File internal appeal within 180 days of denial. 2. If state step-therapy override law applies, cite it in your appeal letter. 3. Standard internal appeal decision: 30 days (pre-service). 4. After final internal denial: request external review within 4 months.

Next steps

Locate the notice-specific filing date and confirm what event starts the period before relying on it.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the claim file in writing and cite the access right stated in the notice or governing rule.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

Upload the current denial notice to organize a draft for review. Confirm the payer criteria, governing sources, clinical facts, deadline, price, and any promotion shown at checkout before relying on them. The treating clinician reviews and signs clinical assertions.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield AAT Augmentation

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.